Exelixis shares tumble as revenue miss

Published 28/07/2025, 21:22
Updated 29/07/2025, 15:29
Exelixis shares tumble as revenue miss

Investing.com -- Exelixis, Inc. (NASDAQ:EXEL) shares plunged 10.2% after the biopharmaceutical company reported second-quarter revenue that fell short of analyst expectations.

The cancer-focused drugmaker posted adjusted earnings per share of $0.75 for the second quarter, exceeding the analyst estimate of $0.64. However, revenue came in at $568.3 million, missing the consensus estimate of $578.46 million, despite showing growth compared to the $637.2 million reported in the same quarter last year. The company also maintained its full-year 2025 revenue guidance of $2.25-2.35 billion, with the midpoint of $2.3 billion falling below analyst expectations of $2.341 billion.

"Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on key commercial, development and pipeline milestones," said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis. "While early in the launch, we’re very pleased with the reception that CABOMETYX has received in advanced neuroendocrine tumors."

The company reported that net product revenues increased to $520.0 million from $437.6 million in the same period last year, primarily due to higher sales volume. However, collaboration revenues dropped significantly to $48.2 million from $199.6 million YoY, largely due to the absence of a $150 million commercial milestone recognized in the second quarter of 2024.

Research and development expenses decreased to $200.4 million from $211.1 million in the comparable period of 2024, while selling, general and administrative expenses rose slightly to $134.9 million from $132.0 million.

The company highlighted progress in its pipeline, including positive topline results from the STELLAR-303 pivotal study for zanzalintinib in colorectal cancer, and completion of enrollment in the STELLAR-304 study in non-clear cell renal cell carcinoma.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.